在 中文 中使用 造血干细胞 的示例及其翻译为 英语
{-}
-
Political
-
Ecclesiastic
-
Programming
岁以下患者应积极进行造血干细胞移植；.
Patients under 50 years old should actively undergo hematopoietic stem cell transplantation;年：在人脐带血中发现了造血干细胞。
Haematopoietic stem cells are discovered in human cord blood.造血干细胞和其前体：发展的多样性和沿袭关系。
并于今年3月进行了造血干细胞移植。
This cord blood stem cell transplant took place last year.Runx1表达标志着长期造血干细胞在妊娠中期小鼠胚胎。
Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo.Combinations with other parts of speech
下一篇：什么是造血干细胞移植？?
Next Page: What is a Blood Stem Cell Transplant?这种造血干细胞就像种子一样。
Those stem cells are kind of like seeds.它从未与造血干细胞中的突变关联在一起。
It's never been linked to mutations in the blood-forming cells.月17日将进行造血干细胞移植。
这是第四次慢性疾病造血干细胞移植(HSCT)出现逆转。
This is the fourth chronic disease hematopoietic stem cell transplantation(HSCT) has appeared to reverse.这种新的治疗方法可清除超过98%的造血干细胞，从而使其像化疗和放疗一样有效。
The new treatment removes more than 98% of blood stem cells, making it as effective as chemotherapy and radiation.根据国家心脏，肺和血液研究所，造血干细胞移植是镰状细胞病唯一的治疗方法。
According to the National Heart, Lung and Blood Institute, hematopoietic stem cell transplants are the only cure for sickle 静脉输入最低的剂量出现在MSC和造血干细胞共移植的临床实验中，为0.3x10*5/kg。
The lowest dose of intravenousinjection appeared in clinical trials of MSC and hematopoietic stem cell co-transplantation, which was 0.3x10* 5/ kg.使用慢病毒载体来取代在造血干细胞中的突变基因，科学家成功地治疗两种罕见疾病，且没有造成有害的副作用。
Using lentiviral vectors to replace mutated genes in blood stem cells, scientists successfully treat two rare diseases apparently without causing harmful side effects.然后研究人员修改了某些造血干细胞的DNA，以便携带SHIV杀伤CAR。
Then the researchers modified the DNA of certain blood-forming stem cells so they would carry SHIV-killing CAR.考虑到治疗病人所需的造血干细胞数量，这是一个很大的数字."米克科拉教授说。
If we think about the amount of blood stem cells needed to treat a patient, that's a significant number," commented Mikkola.造血干细胞的取决于Galpha(s)-介导的信号来嫁接骨髓。
Haematopoietic stem cells depend on Galpha(s)-mediated signalling to engraft bone marrow.白血病是一种影响造血干细胞或血细胞的癌症，通常是产生免疫反应的白血球。
Leukemia is a cancer that affects blood-forming stem cells or blood 治疗选择包括类固醇、化疗和造血干细胞移植(HSCT)。
Treatment options include steroids, chemotherapy and hematopoietic stem cell transplant(HSCT).然而，在有些病例里，突变赋予了一些造血干细胞一丝生存的希望，加重了它们在生产血细胞方面扮演的角色。
In some cases, however, the mutations give certain HSCs an edge in survival, granting them an outsized role in producing blood cells.这项研究发现，在胎儿发育过程中，“母体”造血干细胞停留在肝脏中。
The research discovered that during development,‘mother' haematopoietic stem cells stay in the liver.这些造血干细胞非常稀有，分裂缓慢，而且同时具有自我更新和分化成其他各种类型血细胞的能力。
These blood stem cells were rare, slow to divide, and capable of both self-renewal and differentiation into any of the blood's more specialized 这一成就标志着任何研究小组首次产生这种造血干细胞。
The achievement marks the firsttime that any research group has generated such blood-forming stem cells.异基因造血干细胞移植：可以大大提升治疗效果，主要用于有合适提供者的年轻患者。
Allogeneic hematopoietic stem cell transplantation: can greatly improve the treatment effect and is mainly used to young patients who have suitable providers.使用造血干细胞移植的主要障碍包括供体细胞的供应有限和缺乏有效的收集方法。
Major barriers to using hematopoietic stem cell transplantation include the limited supply of donor 首先，从患者的骨髓或血液中收集造血干细胞（HSC）或者成血细胞，并冷冻直至需要为止。
Firstly, hematopoietic stem cells(HSCs), or hemocytoblasts, are collected from the patient's bone marrow or blood and are frozen until they are needed.在近20年的时间里，科学家们一直在想方设法利用人类胚胎干细胞来培养造血干细胞。
For almost 20 years, scientists have been searching for a way to usehuman embryonic 造血干细胞是可自行支配的最好的治疗工具，因为他们在体内可以分化成任何一种血液细胞。
HSCs are one of the best therapeutic tools at our disposal because they can make any blood cell in the body.Musashi-2的蛋白质调节重要造血干细胞的功能和发育的机制.
A protein called Musashi-2 regulates the function anddevelopment of important blood stem cells.在胚胎发育的早期阶段，具有确定任务的干细胞（包括造血干细胞）逐渐出现。
In the early stage of embryonic development, 
